Anti-angiogenic therapy in the treatment of advanced renal cell cancer

被引：18

作者：

Board, Ruth E. ^{[1
]}

Thistlethwaite, Fiona C. ^{[1
]}

Hawkins, Robert E. ^{[1
]}

机构：

[1] Christie Hosp NHS Trust, Dept Med Oncol, Canc Res UK, Manchester M20 4BX, Lancs, England

来源：

CANCER TREATMENT REVIEWS | 2007年 / 33卷 / 01期

关键词：

renal cell cancer; VEGF; bevacizumab; sorafenib; sunitinib; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR INHIBITOR; PHASE-II; INTERFERON-ALPHA; ANTITUMOR-ACTIVITY; SINGLE-AGENT; TUMOR-GROWTH; RAF KINASE; SU5416;

D O I：

10.1016/j.ctrv.2006.08.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：1 / 8

页数：8

共 63 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2]

[Anonymous], J CLIN ONCOL

[3]

[Anonymous], CANC PRINCIPLES PRAC

[4]

[Anonymous], 2005, J. Clin. Oncol.

[5]

[Anonymous], J CLIN ONCOL S

[6] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[7] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours [J].

Awada, A ;

Hendlisz, A ;

Gil, T ;

Bartholomeus, S ;

Mano, M ;

de Valeriola, D ;

Strumberg, D ;

Brendel, E ;

Haase, CG ;

Schwartz, B ;

Piccart, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1855-1861

[8]

Bukowski R., 2006, Journal of Clinical Oncology: ASCO Annual Meeting Proceedings, V24, P4523

[9] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[10] Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors [J].

Clark, JW ;

Eder, JP ;

Ryan, D ;

Lathia, C ;

Lenz, HJ .

CLINICAL CANCER RESEARCH, 2005, 11 (15) :5472-5480

← 1 2 3 4 5 6 7 →